Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
Revenue of Ipca Laboratories Limited (IPCALAB.NS)
Revenue in 2023 (TTM): $912.61 M
According to Ipca Laboratories Limited's latest financial reports the company's current revenue (TTM) is $912.61 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ipca Laboratories Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $912.61 M | $575.38 M | $157.51 M | $99.8 M | $64.82 M |
| 2022 | $739.52 M | $466.36 M | $124.67 M | $88.26 M | $55.82 M |
| 2021 | $682.92 M | $433.51 M | $163.24 M | $134.5 M | $104.7 M |
| 2020 | $632.53 M | $419.15 M | $190.6 M | $163.59 M | $135.01 M |
| 2019 | $539.89 M | $337.51 M | $115.7 M | $87.51 M | $71.81 M |
| 2018 | $437.27 M | $284.45 M | $88.75 M | $64.72 M | $52.68 M |
| 2017 | $379.76 M | $240.46 M | $58.58 M | $34.41 M | $28.35 M |
| 2016 | $372.98 M | $235.11 M | $54.59 M | $32.01 M | $24.02 M |
| 2015 | $336.97 M | $205.55 M | $37.24 M | $13.66 M | $11.46 M |
| 2014 | $369.1 M | $225.81 M | $67.8 M | $42.76 M | $30.69 M |
| 2013 | $384.54 M | $244.21 M | $90.42 M | $74.68 M | $56.63 M |
| 2012 | $328.5 M | $192.78 M | $68.35 M | $53.8 M | $38.41 M |
| 2011 | $279.35 M | $171.2 M | $56.34 M | $43.15 M | $32.81 M |
| 2010 | $222.95 M | $131 M | $49.68 M | $40.35 M | $31.13 M |
| 2009 | $184.7 M | $108.24 M | $41.32 M | $31.53 M | $24.32 M |
| 2008 | $152.04 M | $91.96 M | $22.48 M | $14.01 M | $11.94 M |
| 2007 | $124.47 M | $69.54 M | $27.02 M | $20.76 M | $16.1 M |
| 2006 | $111.22 M | $63.7 M | $24.42 M | $18.27 M | $14.94 M |
| 2005 | $89.5 M | $25.08 M | $13.34 M | $8.82 M | $7.28 M |
| 2004 | $80.42 M | $24.24 M | $14.42 M | $11.15 M | $8.77 M |